Skip to main content
Caplight Logo









Azura Ophthalmics

Azura Ophthalmics

Private
Tel AvivHealthcare & Life Scienceshttps://azuraophthalmics.com/

Last Round

Series C

Oct 22, 2020

Total Funding Raised

$37.2M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Azura Ophthalmics is a clinical-stage biopharmaceutical company developing a new class of Ophthalmic Keratolytics for the treatment of Meibomian gland dysfunction (MGD) and other ocular surface diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

Meibomian Gland DysfunctionMGDophthalmic keratolyticDry Eye DiseaseDEDdry eye treatmentkeratolyticocular surface diseaseclinical stage biopharmaophthalmology drugfirst-in-class drugophthalmic ointmentdrug developmentselenium sulfideContact Lens DiscomfortCLD

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Azura Ophthalmics Comparables

Compare Azura Ophthalmics with similar companies based on industry and business-model similarity.

Azura Ophthalmics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Novaliq
84%
Stuart Therapeutics, Inc.
77%
Aldeyra Therapeutics
76%

Azura Ophthalmics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series COct 22, 2020
Series BOct 10, 2017
Series AMar 11, 2014

Key People

Founding team and executive leadership

Marc Gleeson

Chief Executive Officer

Executive Team

Ashwin Agarwal

Chief Financial Officer

Executive Team

Azura Ophthalmics Investors

Notable investors and investment history

Azura Ophthalmics investors
InvestorRounds
Ganot CapitalSeries B, Series A, Series C
OrbiMedSeries B, Series C
TPG BiotechSeries B, Series C
Elron VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 5304% MoM, from 25 to 1.4K.

  • May 1, 2025

    Monthly visitors increased 77% MoM.

Azura Ophthalmics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Azura Ophthalmics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Azura Ophthalmics's valuation, stock price, and market status.

Firmographic Details

HeadquartersTel Aviv
Employee Range8
Year Founded2014
Last FundingOct 22, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?